Berberine Ursodeoxycholate (HTD1801) Improves Key Glycemic and Cardiometabolic Parameters across the Type 2 Diabetes Mellitus Disease Spectrum

被引：0
|
作者：
Ji, Linong
Ma, Jianhua
Ma, Yujin
Cheng, Zhifeng
Gan, Shenglian
Yuan, Guoyue
Liu, Dexue
Li, Sheli
Liu, Yu
Xue, Xia
Bai, Jie
Wang, Kun
Cai, Hanqing
Li, Shu
Liu, Kui
Yu, Meng
Liu, Liping
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-847-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
847-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy of berberine ursodeoxycholate (HTD1801) in Chinese and Western patients with type 2 diabetes
    Gan, S.
    Ji, L.
    Ma, J.
    Cheng, Z.
    Gunn, N. T.
    Neff, G. W.
    Liu, K.
    MacConell, L.
    DIABETOLOGIA, 2024, 67 : S341 - S341
  • [2] EFFECTS OF HTD1801 (BERBERINE URSODEOXYCHOLATE) ON NON-INVASIVE FIBROSIS MARKERS IN SUBJECTS WITH PRESUMED NASH AND TYPE 2 DIABETES
    Harrison, Stephen A.
    Gunn, Nadege
    Neff, Guy W.
    MacConell, Leigh
    Loomba, Rohit
    HEPATOLOGY, 2021, 74 : 1136A - 1137A
  • [3] EFFECTS OF HTD1801 (BERBERINE URSODEOXYCHOLATE) ON THE GUT MICROBIOTA IN THREE RODENT MODELS OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES
    Bai, Ru
    Yu, Meng
    Liu, Liping
    Di Bisceglie, Adrian M.
    HEPATOLOGY, 2022, 76 : S1288 - S1288
  • [4] REDUCTION IN LIVER FAT CONTENT WITH HTD1801 (BERBERINE URSODEOXYCHOLATE) IS CLOSELY ASSOCIATED WITH IMPROVED GLYCEMIC CONTROL, WEIGHT LOSS, AND REDUCED ALT
    Harrison, Stephen A.
    Gunn, Nadege T.
    Neff, Guy W.
    Kohli, Anita
    Hirman, Joseph W.
    Di Bisceglie, Adrian M.
    HEPATOLOGY, 2021, 74 : 94A - 95A
  • [5] Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus
    Harrison, Stephen
    Gunn, Nadege
    Neff, Guy
    Flyer, Abbey
    Liberman, Alexander
    MacConell, Leigh
    JOURNAL OF HEPATOLOGY, 2023, 78 : S653 - S654
  • [6] TIME COURSE OF ONSET, INCIDENCE AND PREVALENCE OF GASTROINTESTINAL ADVERSE EVENTS WITH HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH MASH AND T2DM
    Neff, Guy
    Harrison, Stephen
    Gunn, Nadege
    Flyer, Abigail
    Liu, Kui
    Liberman, Alexander
    HEPATOLOGY, 2024, 80
  • [7] Time course of onset, incidence and prevalence of gastrointestinal adverse events with HTD1801 (Berberine Ursodeoxycholate) in patients with MASH and T2DM
    Neff, Guy
    Harrison, Stephen A.
    Gunn, Nadege
    Flyer, Abigail
    Liu, Kui
    Liberman, Alexander
    JOURNAL OF HEPATOLOGY, 2024, 80 : S618 - S618
  • [8] EVALUATION OF EFFICACY OF BERBERINE URSODEOXYCHOLATE (HTD1801) COMPARED TO ONGOING USE OF GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH MASH AND T2DM
    Harrison, Stephen
    Neff, Guy
    Gunn, Nadege
    Flyer, Abigail
    MacConell, Leigh
    HEPATOLOGY, 2024, 80
  • [9] Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM
    Harrison, Stephen A.
    Neff, Guy
    Gunn, Nadege
    Flyer, Abigail
    MacConell, Leigh
    JOURNAL OF HEPATOLOGY, 2024, 80 : S614 - S615
  • [10] HTD1801 improves glycaemic control in patients with type 2 diabetes: double-blind, placebo-controlled, phase 2 study
    Ji, L.
    Ma, J.
    Ma, J.
    Cheng, Z.
    Gan, S.
    Yuan, G.
    Liu, D.
    Li, S.
    Liu, Y.
    Xue, X.
    Bai, J.
    Wang, K.
    Cai, H.
    Li, S.
    Liu, L.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S318 - S319
12345